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ABSTRACT
Dose delivery (total emitted dose, or TED) from dry powder inhalers (DPIs), pulmonary de-
position, and the biological effects depend on drug formulation and device and patient char-
acteristics. The aim of this study was to measure, in vitro, the relationship between parame-
ters of inhalation profiles recorded from patients, the TED and fine particle mass (FPM) of
Diskus and Turbuhaler inhalers. Inhalation profiles (IPs) of 25 patients, a representative sam-
ple of a wide range of 1500 IPs generated by 10 stable asthmatics, 3  16 (mild/moderate/se-
vere) COPD patients and 15 hospitalized patients with an exacerbation asthma or COPD, were
selected for each device. These 25 IPs were input IPs for the Electronic Lung (a computer-
driven inhalation simulator) to determine particle size distribution from Ventolin Diskus and
Inspyril Turbuhaler. The TED and FPM of Diskus and FPM of Turbuhaler were affected by
the peak inspiratory flow (PIF) and not by slope of the pressure-time curve, inhaled volume
and inhalation time. This flow-dependency was more marked at lower flows (PIF  40 L/min).
Both the TED and FPM of Diskus were significantly higher as compared to those of the Tur-
buhaler [mean (SD) TED_diskus (%label claim) 83.5 (13.9) vs. TED_turbuhaler (72.5 (11.1) (p 
0.004), FPM_diskus (%label claim) 36.8 (9.8) vs FPM_turbuhaler (28.7 (7.7) (p  0.05)]. The TED and
FPM of Diskus and FPM of Turbuhaler were affected by PIF, the flow-dependency being
greater at PIF values below 40 L/min. Lower PIFs occurred more often when using Turbuhaler
than Diskus, since Turbuhaler have a higher resistivity, requires substantially higher pres-
sure in order to generate the same flow as Diskus. TED, dose consistency and the FPM were
higher for Diskus as compared to Turbuhaler. The flow dependency of TED and FPM was
substantially influenced by inhalation profiles when not only profiles of the usual outpatient
population were included but also the real outliers from exacerbated patients.
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INTRODUCTION
THE EFFICACY of inhaled drugs to the lungs in-cludes three steps: dose delivery from the in-
haler (total emitted dose, or TED) that results in
a certain dose to patient, pulmonary deposition
of the TED, and the biological effects of the dose.1
The TED and aerosolisation of drugs delivered
by dry powder inhalers (DPIs) depend on its for-
mulation, device characteristics (e.g., resistance to
1Department of Pulmonary Diseases, Dekkerswald, University of Nijmegen, Groesbeek, The Netherlands.
2GlaxoSmithKline Research & Development Department, Ware, Hertfordshire, United Kingdom.
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airflow, or resistivity), airway characteristics and
patient’s inhalation technique.2 The inspiratory
effort generates a negative pressure drop in the
mouth. The mouth-pressure versus time curve
was defined as the inhalation profile (IP). When
the resistivity is known, the pressure profile can
be converted into a flow profile.3 Peak inspira-
tory flow (PIF),4 slope of pressure versus time,5,6
inhaled volume (Vi),1,7 and inhalation time (Ti)8
are variables of the inhalation profile which may
influence the TED.
Conventionally, the in vitro methods testing the
TED and the fine particle mass (FPM) (the
amount of drugs in the respirable range, 0.5–5
m9) are based on impaction on the Cascade Im-
pactor tested at constant flows. These measure-
ments played an important role in the develop-
ment and optimalisation of inhalation devices.
The relationship between in vitro and in vivo is
still unclear. Most of the particle-size systems op-
erate at constant and fixed flows (30, 60 and 90
L/min) typically from a pump, which do not
mimic the actual patients’ IP.
In the present study, two multidose dry pow-
der inhalers (DPI) were compared in vitro; the In-
spyril Turbuhaler® (AstraZeneca, Sweden) con-
tains 100 doses of 100 g salbutamol (spherical
pellets) stored in a reservoir dosing unit, and the
Ventolin Diskus® (or Accuhaler®, GlaxoSmith-
Kline, UK), which contains 60 individually sealed
metered doses of 200 g salbutamol plus a lac-
tose carrier.
A selection of typical “real life” inhalation pro-
files of patients with asthma and COPD with a
wide range of bronchial obstruction was im-
ported in a computer-driven inhalation simula-
tor, the Electronic Lung (GlaxoSmithKline Re-
search and Development Ware, UK).10 The
purpose of this study was to measure the effects
of the inhalation profile variables on the TED and
FPM. Furthermore, differences of TED and FPM
between the two devices were also assessed.
MATERIALS AND METHODS
Study design
In two previous studies, inhalation profiles
were recorded with the Inhalation Profile
Recorder11,12 (GSK R&D Dept., Ware UK). In 10
stable asthma patients and three groups (mild,
moderate and severe) of 16 COPD patients, 18 in-
halation profiles were recorded for each device
during six sessions over 10 weeks. Also, 15 hos-
pitalized patients participated in a randomized
study of inhalation profiles through placebo de-
vices.13 For each device, triplicate inhalation pro-
files were recorded during day 1–9 of admission
and in stable phase.
Twenty-five inhalation profiles with a wide
range of characteristics were selected for Diskus
and twenty-five inhalation profiles were selected
for Turbuhaler from the total of 3000 profiles 
collected in these studies and were the input for
the Electronic Lung10,14 (GlaxoSmithKline R&D
Dept., Ware UK), which enabled us to measure
TED and the FPM.
Materials used
The study included the use of Ventolin Diskus
inhaler, 200 g/dose (GlaxoSmithKline, UK) and
the Inspyril Turbuhaler inhaler, 100 g/dose (As-
traZeneca, Sweden).
Inhalation profile
The inhalation profiles (pressure vs time) were
recorded by a pressure transducer: the inhalation
profile recorder11 (GSK R&D Dept., Ware UK).
The transducer measured pressures in the mouth-
piece during the inhalation through a placebo
Diskus and Turbuhaler. The variables of the in-
halation profile recorder are pressure slope
[Slope] (kPa/sec), peak pressure drop [PPD]
(kPa), time to peak pressure drop: the time be-
tween the onset of the inhalation and the moment
of reaching the PPD [Tp] (sec) (the start of the
measuring time is the moment that the pressure
passes the 0.2-kPa threshold), peak inspiratory
flow [PIF] (L/min), inhaled volume [Vi] (L) and
inhalation time [Ti] (sec). The relationship be-
tween PIF and PPD was calculated3 by PPD 
PIF  R, where R is the resistivity of the device
[R_diskus  0.02133 (kPa)0.5(L/min)1 and R_tur-
buhaler  0.03223 (kPa)0.5(L/min)1].15
Electronic lung
The Electronic Lung is a computer-driven in-
halation simulator14,16 (Fig. 1). In vivo IPS of pa-
tients were replicated. Next the mass and parti-
cle size distributions of drug delivered from a
Ventolin Diskus and Turbuhaler were deter-
mined. The powder was drawn from the device
into the metal sampling chamber by a computer-
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driven piston, programmed by the IP. Then, the
powder was extracted from the chamber by a sec-
ond pump that was switched on after completion
of the inhalation through an Anderson Cascade
Impactor (Graseby Anderson Ltd, Orpington,
UK) operating at 60 L/min. This was repeated 10
times to obtain a sufficient amount of drug for
analyzing. The total emitted dose (TED) was the
sum of the amounts of drug in the throat inlet,
sampling chamber, and Cascade Impactor. The
cumulative dose of the sampling chamber, throat,
and the preseparator of the Cascade Impactor
was labeled as coarse particle mass (CPM  4.0
m). The accumulated amount of drug on stages
1–5 of the Cascade Impactor represented the fine
particle mass (FPM, 0.76–4.0 m), whereas the
particles on stages 6 and 7 plus the filter were
termed very fine particle mass (VFPM, 0.76
m).
The throat, sampling chamber, preseparator,
and all stages were washed out with a suitable
solvent. The TED, CPM, FPM, and VFPM were
determined by high-performance liquid chro-
matography (HPLC).
Statistical analysis
SPSS for windows version 9.0 was used for cal-
culating means of the inhalation parameters. Data
were expressed as mean  SD. A p value of 0.05
was considered significant.
To select the inhalation profiles which had to be
a representation of the range of the different pro-
files generated in the study, it was assumed that
the profiles were adequately described by PIF,
slope, Vi, and Ti. These parameters were plotted in
a four dimensional hypercube design. Four center
inhalation profiles were selected to give a repre-
sentation of the middle range. Points were taken as
extreme if they were below the 25th percentile or
above the 75th percentile. As far as possible the 16
combinations of the four factors: PIF; slope; Vi and
Ti (each at two levels) were used to select the in-
halation profiles that correspond to these design
points. For each device five extra plots in the low-
est peak flow range were selected. These selection
of inhalation profiles gave the widest span of the
data (not only of the usual outpatient population,
but also outliers from the extremes of disease sever-
ity during exacerbation).
Regression models were fitted (using JMP sta-
tistical software) for TED, FPM as percentage of
label claim and FPM as percentage of TED with
the natural logarithm of PIF as an explanatory
variable. Device differences were also investi-
gated, as was the effect of TED on FPM.
RESULTS
A total of 1500 inhalation profiles through
each device was recorded from asthmatics and
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FIG. 1. The Electronic Lung.
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COPD patients. For both Diskus and Tur-
buhaler, inhalation profiles of 25 patients were
run with the Electronic Lung. The demograph-
ics of the patients from whom the selected 
inhalation profiles were taken, are shown in
Table 1.
Inhalation profile variables
The mean inhalation profile variables are
shown in Table 2. The PIF values of the Diskus
were significantly higher as compared to Tur-
buhaler (mean [SD]: 100.1 [30.8] vs. 69.2 [19.3]
L/min [p  0.001]). The inhalation time of Tur-
buhaler was significantly longer as compared to
Diskus (mean [SD] 3.3 [1.3] vs. 2.5 [1.1] sec [p 
0.03]).
Effect of inhalation profile variables on total
emitted dose
Table 3 shows the Electronic Lung results (TED
and FPM) for both devices.
Initially, the effect of PIF was assessed, since
this is believed to be the most likely variable to
influence the Electronic Lung results.
Figure 2 shows the relationship between TED
and PIF. No significant correlation between PIF
and TED was found for the Turbuhaler. Overall,
the TED for Diskus was significantly higher than
for Turbuhaler, but over a small increase in TED
for Diskus, there appeared to be a slight flow de-
pendency.
Effect of inhalation profile variables on fine
particle mass
Figure 3 shows the FPM (percentage of label
claim), plotted against PIF (L/min). There is a
strong relationship between FPM and PIF, with
FPM increasing as PIF increases. The rate of in-
crease, however, appears to be greater when PIF
is low.
Univariate regression models were fitted for
TED as percentage of label claim, FPM as 
percentage of label claim, and FPM as percent-
age of TED with the Ln(PIF) as an explanatory
variable.
Total emitted dose as percentage of label claim
TED_diskus  54.6 p  3.14E-07 r2  0.57
 30.4  ln(PIF)
TED_turbuhaler  p  0.41 r2  0.57
54.9  4.2  ln(PIF)
Fine particle mass as percentage of label claim
Ln(PIF) and TED both had statistically signifi-
cant effects on FPM (percentage label claim).
There was no additional contribution of the de-
vice type once these effects were accounted for.
FPM  49.4  0.32 p  0.0001 r2  0.88
TED  13.1 ln(PIF)
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TABLE 1. PATIENT CHARACTERISTICS
Diskus Turbuhaler
Parameter Mean (SD) Range Mean (SD) Range
Gender (M/F) 17/8 14/11
Age (years) 66 (9.2) 34–75 66 (10.0) 38–75
FEV1%pr (%) 63 (22.1) 24–106 66 (26.7) 16–105
FEV1 (L) 1.7 (0.7) 0.7–3.3 1.7 (0.8) 0.5–3.3
FEV1/VC (%) 49 (12.9) 25–71 50 (16.6) 22–82
Reversibility (%) 8 (6.6) 2–30 6 (4.0) 0–17




pMDI  spacer 1 4
nebulizer 1 0
FEV1 % pr, forced expiratory volume in 1 sec as percentage of predicted; FEV1, forced expiratory volume in 1 sec;
FEV1/VC, FEV1/vital capacity; reversibility, bronchodilator response of FEV1 (%) related to the predicted value; 
device, device used by the patients in daily life.
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The effect of omitting the lowest PIF 
from the analysis
Recalculations of the fit without the lowest
flows (PIF_diskus 23 L/min and PIF_turbuhaler 22
L/min) were performed.
TED_diskus (% label p  0.002 r2  0.51
claim)  3.6 
19.5  ln(PIF)
TED_turbuhaler (% label p  0.045 r2  0.51
claim)  123.4 
11.8  ln(PIF)
FPM (% label claim)  p  0.0001 r2  0.80
48.6  0.32 TED 
12.8  ln(PIF)
The r-squared values for each of the two regres-
sion models are not significantly different, and
there is no evidence that the model parameters
change when the low flow data are omitted.
The residuals from these models have been
plotted against the other inhalation profile vari-
ables (slope, Vi, and Ti). There was no indication
for any other significant relationships.
Differences between the two devices
The Total Emitted Dose was significantly
higher and marginally more variable overall for
Diskus than for Turbuhaler (83.5 [13.9] vs. 72.5
[11.1]% label claim, p  0.004). There did not ap-
pear to be an effect due to device type at compa-
rable inspiratory flows. The Turbuhaler having a
higher resistivity, required substantially higher
pressure, in order to generate the same flow at
Diskus (Figs. 2 and 3).
DISCUSSION
The results of this study showed that the TED
of Diskus was affected by the PIF, and no signif-
icant correlation between PIF and TED_turbuhaler
was found. The FPM of Turbuhaler and Diskus
were dependent of PIF and TED. These flow de-
pendencies were more marked at the lower peak
inspiratory flows (PIF  40 L/min). Both the TED
and FPM of Diskus were significantly higher as
compared to Turbuhaler.
The aim of this study was to determine in vitro
the drug delivery characteristics in respect of the
delivered dose and particle size distribution of
Diskus and Turbuhaler in asthma and COPD pa-
tients using real-life patient inhalation profiles.
Inhalation profiles of these patients with a wide
range of bronchial obstruction and inspiratory
muscle function were replayed through the Elec-
tronic Lung: a computer-driven inhalation ma-
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TABLE 2. INHALATION PROFILE VARIABLES
Mean (SD) [range] Diskus Turbuhaler
PIF (L/min) 100.1 (30.8) [23.3–140.1]* 69.2 (19.3) [22.1–98.8]
Slope (kPa/sec) 13.2 (8.0) [1.0–38.2]0 13.7 (9.0) [0.9–32.8]
Vi (L) 2.9 (1.1) [1.0–5.3]0 2.8 (1.4) [1.0–6.1]
Ti (sec) 2.5 (1.1) [1.0–5.0]0 3.3 (1.3) [1.1–5.8]*
Mean inhalation profile variable: PIF, peak inspiratory flow; Vi, inhaled volume; Ti, inhalation Time. *p  0.05 
differences between Diskus and Turbuhaler.
TABLE 3. ELECTRONIC LUNG RESULTS
Ventolin Diskus Inspyril Turbuhaler
Parameter Mean (SD) Range Mean (SD) Range
Total emitted dose (% label claim) 83.5 (13.9)* 25.7–96.5 72.5 (11.1) 41.3–88.8
Total emitted dose (g) 167.1 (27.8)* 51.3–193.0 72.5 (11.1) 41.3–88.8
Fine particle mass (% label claim) 36.8 (9.8)* 1.2–46.1 28.7 (7.7) 5.1–38.2
Fine particle mass (% TED) 42.7 (9.4) 4.7–51.3 39.4 (9.4) 10.5–50.0
Fine particle mass (g) 73.7 (19.5)* 2.4–92.2 28.7 (7.7) 5.1–38.2
Total emitted dose as percentage of label claim; fine particle Mass as percentage of label claim and as percentage
of the total emitted dose. *p  0.05 differences between Diskus and Turbuhaler.
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noeuvre simulator. Conventional cascade im-
pactors operate at constant flows, which is an un-
realistic deviation from the actual flow patterns
with respect to the drug release from the device.
The airflow through a device during a patient’s
inhalation not only varies with time, but also be-
tween inhalations and patients. The Electronic
Lung realistically simulates drug delivery, with
real flow patterns.
The selected inhalation profiles for this in vitro
comparison of Diskus and Turbuhaler showed
significant lower PIF values and higher inhala-
tion times for Turbuhaler. This was due to the dif-
ferent resistivities (resistance to airflow) of both
devices. PIF decreases with increasing resistiv-
ity,17 which subsequently increases the total in-
halation time.18
An appropriate and clinically efficient DPI
should deliver a reliable, consistent dose and a
large FPM, relatively independent of flow. The
latter should possibly be generated with rela-
tively low inspiratory pressures. In general, the
TED for Inspyril Turbuhaler appeared to be sig-
nificantly lower than that for Ventolin Diskus.
This may be due to the fact that the PIF mea-
surements were lower for Turbuhaler.
The present study showed that the TED_diskus
is affected by PIF and is mainly due to one very
low result. Three relatively low TED_turbuhaler re-
sults did not fit well with a linear regression.
There was also an indication that the dependency
of TED on PIF of both devices was more marked
at lower flows.
The relatively high variability of TED for Ven-
tolin Diskus appeared to be a result of one low
result. This suggests that the variation in drug
particle release may decrease with increasing ef-
fort. After fitting separate regression models for
each device, the residual variability for Ventolin
Diskus was less than that for Inspyril Turbuhaler.
This means that the Diskus provided a more con-
sistent dose delivery.
The flow-dependent drug output (TED), con-
sistency of the dose, and number of particles in
the respirable range (FPM) may theoretically lead
to a decreased clinical efficacy in patients who are
not able to generate an adequate flow through
Diskus or Turbuhaler.
Both devices were extensively studied, both in
vitro and in vivo. Our data confirmed the results
of two other studies, which found that a higher
FPM of Fluticasone Diskus was delivered at 60
L/min as compared to 30 L/min.19,20 Also, other
in vitro device evaluations showed that the TED
and FPM of the Turbuhaler increase at higher
PIF.11,20–22 However, in contrast to our results, a
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FIG. 2. The relationship between the total emitted dose (TED) as percentage of label claim and peak inspiratory flow
(L/min). The relationship between TED and peak pressure drop (PPD; kPa) of Diskus and Turbuhaler were also shown.
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consistent dose delivery and FPM, relatively in-
dependent of flow was described by several stud-
ies for Diskus.23,24 Since dose emission properties
are specific for each drug-device product and the
results of this study are only applicable for Ven-
tolin Diskus and Inspiryl Turbuhaler, the conclu-
sions may not be extrapolated for the different
combinations. Another important reason for vari-
ation may be attributed to the unrealistic test con-
ditions in those studies, that only used a fixed
flow Cascade Impactor. Nevertheless, this was
not the first study using the Electronic Lung
methodology. Several studies used the Electronic
lung methodology rather than a fixed flow rate
cascade impactor, which all demonstrate that
dose delivery from the Diskus is independent of
flow.11,25 The reason that our data seem to con-
tradict these studies could be that the data cho-
sen for our evaluation was in the range of 21/25
the extremes of the 1500 inhalation profiles col-
lected for each device. Only 4/25 were selected
from the middle range. This resulted in a popu-
lation of inhalation profiles which included not
only profiles of the usual outpatient population
but also the real outliers from patients at the ex-
tremes of disease severity. These profiles were
also acquired from severely exacerbated patients
to whom a Diskus or Turbuhaler would normally
not have been prescribed. So, the low profiles for
Diskus and Turbuhaler were lower than collected
in other studies. Recalculations of the fit without
the lowest flows (PIF_diskus 23 L/min and PIF_tur-
buhaler 22 L/min) were performed and there was
evidence that these outliers influenced the over-
all results of TED. For TED turbuhaler the slope
was actually negative when the low flow data
were removed. This was presumably influenced
by the lowest TED result belonging to the high-
est PIF. The regression models for FPM (%label
claim) with and without the low flow data were
also calculated, but there was no evidence that
the model parameters change when the low flow
data were omitted.
This study demonstrated that in practice, dif-
ferent devices are not operating at corresponding
flows by patients. Patients are only able to gen-
erate a certain (maximal) inspiratory effort (pres-
sure) irrespective of which inhaler they inhale
through. The inherent resistivity of the given de-
vice will determine the flow achieved through the
device (Figs. 2 and 3). Comparison of the perfor-
mance of inhalation devices with different resis-
tivities at the same PIF must be considered care-
fully, since a particular flow may relate to an
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FIG. 3. The relationship between the fine particle mass (FPM) as percentage of label claim and peak inspiratory flow
(L/min). The relationship between FPM and peak pressure drop (PPD; kPa) of Diskus and Turbuhaler were also
shown.
5450_07_p74-82  2/17/05  12:49 PM  Page 80
entirely different inspiratory effort in each device.
Conventional in vitro measurements were usually
performed with constant fixed flows of 30, 60 and
90 L/min. Nevertheless, the majority of patients
inhaled with higher PIFs through the Diskus. So,
the in vitro results in the PIF range 30–90 L/min
are of high clinical relevance for Turbuhaler, but
less for Diskus. Since the PIF is in general
achieved after the release of the powder, the slope
of the pressure profile (in kPa/sec) was also de-
scribed as an important variable.5,6,11,26 Surpris-
ingly, in the present study PIF seemed to influ-
ence the Electronic Lung results. There was no
indication of a significant relationship with the
other inhalation profile variables. However, it
was shown for Diskus and Turbuhaler that peak
inspiratory flow and slope correlate well in a
wide range of patient groups.27
In conclusion, the TED and FPM of Diskus and
FPM of Turbuhaler for the salbutamol product
were affected by PIF, the flow-dependency being
greater at low PIF (40 L/min). Lower PIFs oc-
curred more often when using Turbuhaler than
Diskus. Dose to patient (TED), dose consistency,
and the mass of particles in the respirable range
were higher for Diskus as compared to Tur-
buhaler. In vitro studies with a constant flow or
with real-life flow profiles yield different results.
The flow dependency of TED and FPM of
Diskus do not agree with other data published.
This is likely to be due to the use of IPs, which
include not only the usual clinical population but
also the real outliers.
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